Abstract | BACKGROUND: METHODS: RESULTS: Five (29.4%) patients achieved a partial response and 2 (11.8%) had stable disease. In 5 of 15 patients (33.3%) who had elevated serum carbohydrate antigen (CA)19-9 levels at the start of treatment the CA19-9 was reduced by more than 50%. The median survival time was 10 months (range, 20 months), with 63.7% and 31.9% of patients alive at 6 and 12 months, respectively. Major adverse reactions in the 15 patients included gastrointestinal toxicities of grade 1 or 2. Only one patient (5.9%) developed grade 3 leucopenia. CONCLUSION:
|
Authors | Akira Togawa, Hideyuki Yoshitomi, Hiroshi Ito, Fumio Kimura, Hiroaki Shimizu, Masayuki Ohtsuka, Hiroyuki Yoshidome, Atsushi Kato, Shigeaki Sawada, Masaru Miyazaki |
Journal | International journal of clinical oncology
(Int J Clin Oncol)
Vol. 12
Issue 4
Pg. 268-73
(Aug 2007)
ISSN: 1341-9625 [Print] Japan |
PMID | 17701005
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Drug Combinations
- Deoxycytidine
- S 1 (combination)
- Tegafur
- Oxonic Acid
- Cisplatin
- Gemcitabine
|
Topics |
- Administration, Oral
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Cisplatin
(administration & dosage, adverse effects, therapeutic use)
- Deoxycytidine
(analogs & derivatives, therapeutic use)
- Drug Combinations
- Drug Resistance, Neoplasm
- Female
- Humans
- Male
- Middle Aged
- Oxonic Acid
(administration & dosage, adverse effects, therapeutic use)
- Pancreatic Neoplasms
(drug therapy, surgery)
- Pilot Projects
- Survival Analysis
- Tegafur
(administration & dosage, adverse effects, therapeutic use)
- Treatment Failure
- Treatment Outcome
- Gemcitabine
|